- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01953783
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
A Phase 1 Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Each participant must meet all of the following inclusion criteria to be enrolled in the study:
- 18 years or older
- Histologic or cytologic diagnosis of advanced or metastatic solid tumor or lymphoma for which no standard, curative, or life-prolonging therapies exist or are effective
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
- Female participants who are postmenopausal for at least 1 year OR are surgically sterile OR if of childbearing potential, agree to practice 2 effective methods of contraception at the same time during the entire study through 90 days after the last dose of study drug OR agree to practice true abstinence
- Male participants who agree to practice effective barrier contraception during the entire study and through 90 days after the last dose of study drug OR agree to practice true abstinence
- Voluntary written consent
- Suitable venous access for the conduct of blood sampling
- Recovered from the reversible effects of prior anticancer therapy
Exclusion Criteria:
Participants meeting any of the following exclusion criteria are not to be enrolled in the study:
- Female participants who are lactating or breastfeeding or have a positive serum pregnancy test
- Serious medical or psychiatric illness that could interfere with the study
- Treatment with any investigational products or radiotherapy within 21 days before the first dose of study drug
- Peripheral neuropathy greater than (>) Grade 2
- Systemic treatment with strong and moderate inhibitors of CYP1A2, strong and moderate inhibitors of CYP3A, or clinically significant CYP3A inducers or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study drug
- Symptomatic brain metastasis. Participants with brain metastases: must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy; and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs)
- Ongoing treatment with corticosteroids
- Major surgery within the 14 days preceding the first dose of study drug
- Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before the first dose of study drug
- Life-threatening illness unrelated to cancer
- Known hepatitis B surface antigen -positive, or known or suspected active hepatitis C infection or human immunodeficiency virus (HIV) positive
- Diagnosed or treated for another malignancy within 2 years before the first dose, OR previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
- Any cardiovascular condition specified in the study protocol
- Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of IXAZOMIB
- History of urinary and/or fecal incontinence
- Inability to comply with study procedures or visit schedule including the requirement for inpatient confinement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IXAZOMIB
Part A: Participants will receive a single dose of 4.1-milligram (mg) [14C]-IXAZOMIB oral solution containing approximately 500-nCurie (nCi) of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, participants may be administered a single 4.0-mg capsule of IXAZOMIB. Participants will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit. Part B: Eligible participants from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Participants may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Participants will continue in this study until disease progression or unacceptable toxicity. |
Part A: Ixazomib 4.1 mg containing approximately 500-nCi [14C]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21. Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of ixazomib, obtained directly from the plasma concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Part A: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Ixazomib
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Time to reach the maximum observed plasma concentration (Cmax), equal to time (hours) to Cmax of ixazomib after administration, obtained directly from the plasma concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Part A: AUC(0-312): Area Under the Plasma Concentration-time Curve From Time 0 to 312 Hrs Post-dose for Ixazomib
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to 312 hrs) post-dose
|
AUC(0-312) is a measure of the area under the plasma concentration time-curve from time zero to 312 hrs post-dose for ixazomib.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to 312 hrs) post-dose
|
Part A: Cmax: Maximum Observed Plasma Concentration of TRA
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Maximum observed plasma concentration (Cmax) of TRA is the peak plasma concentration of TRA, obtained directly from the plasma TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Tmax: Time to Reach the Cmax for TRA
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Time to reach the maximum observed plasma concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the plasma TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: AUC(0-816): Area Under the Plasma Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
AUC(0-816) is a measure of the area under the plasma concentration time-curve from time zero to 816 hrs post-dose for TRA.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
Part A: Cmax: Maximum Observed Whole Blood Concentration of TRA
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Maximum observed whole blood concentration (Cmax) of a TRA is the peak whole blood concentration of TRA, obtained directly from the whole blood TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Tmax: Time to Reach the Maximum Observed Whole Blood Concentration (Cmax) for TRA
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Time to reach the maximum observed whole blood concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the whole blood TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: AUC(0-816): Area Under the Whole Blood Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
AUC(0-816) is a measure of the area under the whole blood concentration time-curve from time zero to 816 hrs post-dose for TRA.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
Part A: Cumulative Percentage of Ixazomib Dose Recovered in the Urine
Time Frame: Day 1 of Part A from 0 to pre-dose and at multiple timepoints (up to 168 hrs) post-dose
|
Percentage of the ixazomib dose excreted unchanged in the urine from 0 to 168 hrs post-dose.
|
Day 1 of Part A from 0 to pre-dose and at multiple timepoints (up to 168 hrs) post-dose
|
Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Feces
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Percentage of the TRA dose excreted in feces from Day 1 to Day 35 of Part A
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Urine
Time Frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Percentage of the TRA dose excreted in urine from Day 1 to Day 35 of Part A.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Renal Clearance of Ixazomib
Time Frame: Day 1 pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Renal clearance is the volume of plasma from which ixazomib is completely removed by the kidney in a given amount of time, calculated as the amount of ixazomib excreted in the urine divided by the area under the plasma ixazomib concentration-time curve.
|
Day 1 pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ixazomib and Metabolites as Percent of Total Radioactivity in Plasma
Time Frame: Day 1 pre-dose and at multiple time points (up to 816 hrs) post-dose
|
The plasma samples were pooled for participants over 816 hrs post-dose, and data was analysed using the Hamilton method time-proportional pooling, and therefore the data is reported as "percent of total radioactivity in plasma" with measure type as "number" and measure dispersion as "Not applicable, NA".
|
Day 1 pre-dose and at multiple time points (up to 816 hrs) post-dose
|
Ixazomib and Metabolites as Percent of Total Dose Administered in Urine
Time Frame: Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled urine.
The data is therefore reported as "percentage of dose" with measure type as "number" and measure dispersion as "NA".
|
Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
Ixazomib and Metabolites as Percent of Total Dose Administered in Feces
Time Frame: Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled feces.
The data is therefore reported as "percentage of dose" with measure type as "number" and measure dispersion as "NA".
|
Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
Number of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Baseline up to Cycle 5 Day 45
|
Baseline up to Cycle 5 Day 45
|
|
Number of Participants With TEAEs Related to Investigations System Organ Class for Laboratory Values
Time Frame: Baseline up to Cycle 5 Day 45
|
Baseline up to Cycle 5 Day 45
|
|
Number of Participants With TEAEs Related to Vital Signs
Time Frame: Baseline up to Cycle 5 Day 25
|
Vital signs included oral body temperature, heart rate, and blood pressure.
|
Baseline up to Cycle 5 Day 25
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C16016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalTG TherapeuticsTerminatedLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
Clinical Trials on IXAZOMIB
-
Mayo ClinicTakedaCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
SCRI Development Innovations, LLCMillennium Pharmaceuticals, Inc.CompletedMultiple MyelomaUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors | Hematologic MalignanciesUnited States
-
Millennium Pharmaceuticals, Inc.CompletedFollicular LymphomaUnited States, United Kingdom, Belgium, Canada
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Non-hematologic MalignanciesUnited States, Canada
-
Multiple Myeloma Research ConsortiumEli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaboratorsRecruitingRelapsed Refractory Multiple MyelomaUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
University of Wisconsin, MadisonMillennium Pharmaceuticals, Inc.Completed
-
Millennium Pharmaceuticals, Inc.Completed